Home / Resources / Pharma R&D Annual Review 2024 Infographic

Pharma R&D Annual Review 2024 Infographic

Infographic
Clinical
Infographic Banner for Pharma R&D Annual Review 2024

The temporary freeze brought on by the COVID-19 pandemic is well and truly over, as 2023 saw a new high in the number of drugs in development. However, while there are signs the industry is continuing to grow, the forecast is decidedly mixed.

View related products
Healthcare professional monitoring and analyzing R and D trends.
Pharmaprojects
The industry standard for tracking and analyzing the global drug R&D landscape
Professional using a laptop device to access Trialtrove for trial insights and strategy.
Trialtrove
The go-to resource for informing clinical trial strategy, design and execution
Expert analyst presenting data insights on a projected screen.
Biomedtracker
Real-time tracking and analysis of the drug development pipeline

Related resources

Citeline subscribers accessing the 2023 Deal-Making Roundup white paper reported by Biomedtracker.
MAR 28, 2024
White paper
Commercial

2023 Deal-making Roundup

An overview of alliance, M&A, and financing deal activity across the
worldwide biopharma, medical device, and in vitro diagnostics
industries in 2023

''
Clinical

Pharma R&D Annual Review 2024

For over 30 years, the Pharma R&D Annual Review has tracked how the climate is shifting. Browse our resources to help you navigate the climate.

Ingredients for a Deal-Rich Year Infographic banner
APR 23, 2024
Infographic
Clinical

Ingredients for a Deal-rich Year

The global biopharma industry is poised for a deal-rich year, thanks to a variety of factors, including growing momentum in bolt-on M&A activity.

View All Resources